Higher FOBT (faecal occult blood test) test reimbursement "dependent on specificity"
This article was originally published in Clinica
Executive Summary
Medicare's open experimentation with cost as one of the factors in making a national coverage determination is so far setting a high bar for manufacturers. A cost-effectiveness study by the Agency for Healthcare Research & Quality (AHRQ) has concluded that a new version of the faecal occult blood test - IFOBT - designed to detect blood in the stool is a cost-effective intervention for reducing colorectal cancer incidence.